Free Trial

BioNTech (BNTX) Competitors

BioNTech logo
$110.05 +0.05 (+0.05%)
Closing price 04:00 PM Eastern
Extended Trading
$110.07 +0.02 (+0.02%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BNTX vs. GSK, TAK, ARGX, ONC, TEVA, INSM, SMMT, ITCI, GMAB, and RDY

Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

BioNTech vs. Its Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

15.7% of GSK shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

GSK presently has a consensus price target of $37.38, indicating a potential downside of 2.19%. BioNTech has a consensus price target of $137.86, indicating a potential upside of 25.27%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
8 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.10
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.83

In the previous week, GSK had 13 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for GSK and 2 mentions for BioNTech. GSK's average media sentiment score of 0.87 beat BioNTech's score of 0.47 indicating that GSK is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
9 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$40.10B1.95$3.29B$1.9419.70
BioNTech$2.98B8.89-$719.92M-$3.40-32.37

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK9.89% 48.82% 11.15%
BioNTech -27.37%-3.94%-3.41%

Summary

GSK beats BioNTech on 10 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNTX vs. The Competition

MetricBioNTechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$26.45B$2.86B$5.45B$8.93B
Dividend YieldN/A2.44%5.22%4.01%
P/E Ratio-32.3720.4427.2420.06
Price / Sales8.89283.79426.37117.54
Price / CashN/A41.7026.2128.59
Price / Book1.267.397.925.56
Net Income-$719.92M-$55.04M$3.17B$248.56M
7 Day Performance3.36%3.43%4.40%7.56%
1 Month Performance1.44%0.16%2.64%8.54%
1 Year Performance37.41%4.49%35.04%21.81%

BioNTech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTX
BioNTech
2.3746 of 5 stars
$110.05
+0.0%
$137.86
+25.3%
+36.9%$26.45B$2.98B-32.376,772
GSK
GSK
2.3336 of 5 stars
$38.38
-0.5%
$37.38
-2.6%
-1.5%$78.58B$31.53B19.7890,100
TAK
Takeda Pharmaceutical
1.2768 of 5 stars
$15.46
+2.4%
N/A+17.7%$49.19B$30.09B70.2847,300
ARGX
argenex
4.3708 of 5 stars
$551.22
-1.6%
$729.93
+32.4%
+24.7%$33.66B$2.58B34.00650High Trading Volume
ONC
BeOne Medicines
2.988 of 5 stars
$242.07
+0.4%
$320.67
+32.5%
N/A$26.53B$3.81B-65.079,000
TEVA
Teva Pharmaceutical Industries
4.218 of 5 stars
$16.76
flat
$24.13
+43.9%
+4.0%$19.22B$16.54B-14.5736,800Positive News
Options Volume
INSM
Insmed
4.5598 of 5 stars
$100.64
+1.2%
$106.80
+6.1%
+40.7%$19.09B$363.71M-16.91740Positive News
SMMT
Summit Therapeutics
2.4826 of 5 stars
$21.28
+3.3%
$35.09
+64.9%
+236.3%$15.80B$700K-62.59110Gap Down
ITCI
Intra-Cellular Therapies
0.9401 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.8546 of 5 stars
$20.66
+0.8%
$37.60
+82.0%
-20.1%$13.25B$3.12B11.742,682
RDY
Dr. Reddy's Laboratories
2.6856 of 5 stars
$15.03
-0.3%
$16.95
+12.8%
-3.4%$12.55B$3.81B22.7727,811

Related Companies and Tools


This page (NASDAQ:BNTX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners